Federal Circuit rejects bio patent citing Bilski
22 December 2008
Eileen McDermott, New York
A patent covering diagnostic method claims was rejected by the US Court of Appeals for the Federal Circuit on Friday based on the Court’s controversial decision in In re Bilski, which changed the test for determining patent-eligible subject matter in the US
Although the opinion was non-precedential, it could have significant implications for the biotechnology industry.
The patent at issue (number 5,723,283) covers a "method of immunization, and compositions therefore ... for substantially preventing or reducing the symptoms of at least one infectious disease and at least one chronic immune mediated disorder", which involves immunising patients and analysing the results.
The inventor, John Barthelow Classen and Classen Immunotherapies, accused Biogen, GlaxoSmithKline and Merck &...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial